Printer Friendly

NIAID Awards Integrated BioTherapeutics USD 6.6m Grant for Development of Pan-Ebolavirus Vaccine in Collaboration with The Scripps Research Institute.

M2 PHARMA-August 4, 2017-NIAID Awards Integrated BioTherapeutics USD 6.6m Grant for Development of Pan-Ebolavirus Vaccine in Collaboration with The Scripps Research Institute


- Rockville, Maryland-based infectious disease treatment developer Integrated BioTherapeutics Inc. (IBT) has been awarded a USD6.6 m grant by the National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine that can protect against all ebolaviruses, the company said.

The research is led by co-principal investigators Dr. M. Javad Aman, chief scientific officer at IBT, and Drs. Erica Ollmann Saphire and William R. Schief at The Scripps Research Institute (TSRI), La Jolla, California.

The filoviruses Ebola, Sudan, Bundibugyo, and Marburg are highly pathogenic and cause hemorrhagic fever in humans.

They rely on a single protein on their surface, termed glycoprotein, to infect humans. Because of its surface location, filovirus glycoproteins are primary targets for vaccine development.

Although EBOV vaccination efforts have shown tremendous promise, current candidate vaccines provide no protection against other filoviruses that also present an outbreak risk.

Recently, this team of investigators and others demonstrated that broadly neutralizing antibodies exist that neutralise and protect against all ebolaviruses, raising the hope that a broadly protective vaccine can be developed.

Using state-of-the-art approaches for immunogen design, the investigators will use EBOV glycoprotein as a basis for the rational design and production of pan-ebolavirus vaccine candidates to promote broadly protective immune responses that target vulnerable structural sites shared among all ebolaviruses.

During the five-year funding period, the team will first examine the immune response and protection of mice and guinea pigs to select highly active, engineered immunogens.

Next, the selected immunogens will be tested again in rodents and then in nonhuman primates to identify promising candidates for advanced preclinical development.

Upon completion of this research, IBT anticipates transitioning the most promising candidates toward advanced development, including clinical testing and licensure by the Food and Drug Administration.

IBT is focused on the discovery of novel vaccines and therapies for emerging infectious diseases with a pipeline that includes product candidates for bacterial and viral infections, including unique pan-filovirus immunotherapeutics and vaccines, vaccines for Staphylococcal infections, and a variety of other product candidates for emerging viruses.

The Scripps Research Institute is an independent, not-for-profit organisations focusing on research in the biomedical sciences. The institute employs more than 2,500 people on its campuses in La Jolla, California, and Jupiter, Florida.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1U9CA
Date:Aug 4, 2017
Previous Article:Results of Kite Study of Refractory Aggressive Non-Hodgkin Lymphoma Published in Electronic Edition of BLOOD.
Next Article:NIH Awards BioAxone BioSciences USD 1.5m SBIR Grant.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters